JMP Securities upgraded shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) to an outperform rating in a research note issued to investors on Monday morning. JMP Securities currently has $60.00 price objective on the stock, up from their previous price objective of $10.00.

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

A number of other analysts have also recently commented on SRPT. Vetr cut Sarepta Therapeutics from a hold rating to a sell rating and set a $17.28 target price on the stock. in a research report on Monday, May 23rd. Wedbush reiterated a neutral rating and set a $14.00 target price on shares of Sarepta Therapeutics in a research report on Wednesday, May 25th. Oppenheimer Holdings Inc. reiterated an outperform rating and set a $60.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, May 26th. Robert W. Baird reiterated an outperform rating and set a $23.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, May 26th. Finally, Royal Bank Of Canada reiterated a sector perform rating and set a $5.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, May 26th. Two analysts have rated the stock with a sell rating, four have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $51.01.

Sarepta Therapeutics (NASDAQ:SRPT) opened at 56.22 on Monday. The stock has a 50 day moving average price of $29.05 and a 200 day moving average price of $21.62. Sarepta Therapeutics has a 52-week low of $8.00 and a 52-week high of $58.87. The stock’s market cap is $2.69 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.19) by $0.16. During the same period last year, the business posted ($0.87) earnings per share. On average, equities research analysts forecast that Sarepta Therapeutics will post ($4.17) EPS for the current year.

In other news, VP Jayant Aphale sold 35,000 shares of the business’s stock in a transaction that occurred on Monday, September 19th. The stock was sold at an average price of $50.00, for a total transaction of $1,750,000.00. Following the sale, the vice president now owns 21,490 shares of the company’s stock, valued at approximately $1,074,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Edward M. Md Kaye sold 24,557 shares of the business’s stock in a transaction that occurred on Wednesday, September 14th. The stock was sold at an average price of $30.00, for a total value of $736,710.00. Following the sale, the chief executive officer now directly owns 76,983 shares in the company, valued at approximately $2,309,490. The disclosure for this sale can be found here. Company insiders own 10.90% of the company’s stock.

Several large investors have recently made changes to their positions in SRPT. State Street Corp raised its stake in shares of Sarepta Therapeutics by 54.0% in the first quarter. State Street Corp now owns 2,467,376 shares of the company’s stock valued at $48,168,000 after buying an additional 865,658 shares during the period. Franklin Resources Inc. purchased a new stake in shares of Sarepta Therapeutics during the first quarter valued at approximately $13,506,000. A.R.T. Advisors LLC purchased a new stake in shares of Sarepta Therapeutics during the first quarter valued at approximately $7,461,000. Eagle Asset Management Inc. purchased a new stake in shares of Sarepta Therapeutics during the second quarter valued at approximately $6,756,000. Finally, Emerald Mutual Fund Advisers Trust purchased a new stake in shares of Sarepta Therapeutics during the second quarter valued at approximately $4,712,000. 72.09% of the stock is currently owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.